

해외 바이오의약품 임상 현황 ('24년 3월 1주)

한국바이오의약품협회, 2024.03.12.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.03.04.~2024.03.10.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06054776	Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Drug: Acalabrutinib Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Echocardiography Biological: Glofitamab Procedure: Multigated Acquisition Scan Biological: Obinutuzumab Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06054776
NCT06042725	Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma	Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Chest Radiography Procedure: Computed Tomography Biological: Daratumumab Drug: Dexamethasone Drug: Lenalidomide Procedure: Low Dose Computed Tomography of the Whole Body Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography Drug: Venetoclax Procedure: X-Ray Imaging	Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06042725
NCT05539365	Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer	Biological: Alpha-type-1 Polarized Dendritic Cells Procedure: Biopsy Procedure: Computed Tomography Procedure: Leukapheresis Biological: Pembrolizumab Other: Quality-of-Life Assessment	Roswell Park Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05539365
NCT06131398	A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors	Drug: AMG 355 Drug: Pembrolizumab	Amgen	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06131398
NCT06145035	Single or Repeated Intravenous Administration of umbilical Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy	Biological: umbilical cord-derived mesenchymal stromal cells (UC-MSCs)	Roberto Bolli University of Miami University of Texas United States Department of Defense University of Louisville	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06145035
NCT06088654	Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma	Drug: IPH6501	Innate Pharma	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06088654
NCT05952804	IVIG for Infection Prevention After CAR-T-Cell Therapy	Biological: Immune Globulin Infusion (Human), 10% Solution Biological: Anti-CD19 CAR T Cells Preparation Other: Saline Procedure: Biospecimen Collection Other: Survey Administration Other: Electronic Health Record Review	Fred Hutchinson Cancer Center Takeda National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05952804
NCT05807126	Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Biological: Magrolimab Drug: Olaparib	National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05807126

해외 바이오의약품 임상 현황 ('24년 3월 1주)

한국바이오의약품협회, 2024.03.12.

○ 미국 10건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05643638	A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD	Biological: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) Biological: Placebo Drug: Corticosteroids	Cynata Therapeutics Limited	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05643638
NCT06256588	A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Drug: Dostarlimab Drug: Placebo	GlaxoSmithKline	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06256588

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06256588	A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Drug: Dostarlimab Drug: Placebo	GlaxoSmithKline	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06256588

○ 프랑스 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06256588	A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Drug: Dostarlimab Drug: Placebo	GlaxoSmithKline	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06256588

○ 독일 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06256588	A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Drug: Dostarlimab Drug: Placebo	GlaxoSmithKline	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06256588

○ 중국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06176352	A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia	Drug: Faricimab Drug: Ranibizumab Procedure: Sham Procedure	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06176352

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06256588	A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Drug: Dostarlimab Drug: Placebo	GlaxoSmithKline	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06256588